Karyopharm Therapeutics Inc. (KPTI)

-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In STORM, XPOVIO Achieved a 26%...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Karyopharm Therapeutics Inc.

In trading on Tuesday, shares of Karyopharm Therapeutics Inc crossed below their 200 day moving average of $7.64, changing hands as low as $7.55 per share. Karyopharm Therapeutics Inc shares are currently trading down about 1.4% on the day.

− XPOVIO™ Commercial Launch Underway Following July 3 rd FDA Accelerated Approval − − XPOVIO is the First and Only Prescription Medicine Approved in the U.

NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc.

SAN DIEGO, Aug. 2, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below.

NEWTON, Mass., Aug.

-- Conference Call Scheduled for Tuesday, August 6, 2019 at 8:30 a.m. ET --

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc.

Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.

NEW YORK, July 26, 2019 /PRNewswire/ -- Choice Bancorp, Inc. (CBKW) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of Choice to Nicolet Bankshares, Inc.

NEW YORK, July 26, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc.

SAN FRANCISCO, July 24, 2019 /PRNewswire/ --  Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.

NEW YORK, July 24, 2019 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc.

NEW YORK, July 23, 2019 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") today announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System ("ACERS") against Karyopharm...

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome...

Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the February 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Karyopharm Therapeutics Inc , where a total volume of 11,447 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 112.1% of KPTI's average daily trading volume over the past month, of 1.0 million shares.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

- PDUFA Action Date Extended by Three Months to July 6, 2019 -

As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Investors in Karyopharm Therapeutics Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new December 21st contracts and identified the following put contract of particular interest.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.